Sarika N. Rao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarika N. Rao has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Victor J. Bernet
Department of Endocrinology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224
2 shared publications - Adrian George Dumitrascu
Advisor to residents and Consultant in Hospital Internal Medicine, Mayo Clinic, Jacksonville, FL
1 shared publication - Ana-Maria Sigarteu Chindris
Department of Internal Medicine, Division of Endocrinology, Mayo Clinic Florida , Jacksonville, FL 32224
1 shared publication - Andrew R. Lewis
Division of Interventional Radiology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224
1 shared publication Ashish V Chintakuntlawar
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
1 shared publicationCrystal R Hilger
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication
Latest Publications
- Open Access
- 7 July 2025
- Published by Elsevier in Endocrine Practice
- Vol. 31 (11) , 1399-1406
Hypocalcemia Post Total Thyroidectomy: A Ten-Year, Single Institution Experience With a Parathyroid Hormone-Guided Calcium and Calcitriol Supplementation Protocol
- 7 July 2025
- Published by Elsevier in Endocrine Practice
- Vol. 31 (11) , 1399-1406
Open AccessHypocalcemia Post Total Thyroidectomy: A Ten-Year, Single Institution Experience With a Parathyroid Hormone-Guided Calcium and Calcitriol Supplementation Protocol
- Top Cited Papers
- 26 May 2022
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 37 (1) , 101678
Anaplastic thyroid cancer: An update
- 26 May 2022
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 37 (1) , 101678
Top Cited PapersAnaplastic thyroid cancer: An update
- Open Access
- 22 March 2022
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 6 (5) , bvac044
Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas
Context: Metastatic pheochromocytomas and paragangliomas (mPPGL) are rare vascular neuroendocrine tumors that highly express vascular growth factors. Systemic treatment options in cases of unresectable multisite disease are limited. Multikinase inhibitors that inhibit angiogenesis, such as lenvatinib, have proven effective in several other malignancies, and may be a viable option for mPPGL. Objective: We aimed to evaluate the efficacy of lenvatinib as salvage therapy in mPPGLs. Methods: This was a retrospective analysis of mPPGL patients ≥ 18 years of age who received lenvatinib from 2015 to 2020 at a tertiary referral center. Patients were started on lenvatinib 20 mg daily and dose was adjusted according to tolerance or disease progression. Results: Eleven patients were included. Median treatment duration was 14.7 months (95% CI, 2.3-NE). Treatment was discontinued due to disease progression, adverse events, or death. Overall survival at 12 months was 80.8% (95% CI, 42.3-94.9%) but its median was not reached. Median progression-free survival was 14.7 months (95% CI, 1.7-NE). Among the 8 patients with measurable disease, overall response rate was 63%, as 5/8 experienced a partial response and 3/8 had stable disease. Worsening hypertension and anemia were the most common adverse events. Conclusion: Lenvatinib may be a viable treatment option for mPPGL, although at the potential risk of worsening hypertension. Larger, multicenter studies are needed to better characterize treatment efficacy.
- 22 March 2022
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 6 (5) , bvac044
Open AccessLenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas
Context: Metastatic pheochromocytomas and paragangliomas (mPPGL) are rare vascular neuroendocrine tumors that highly express vascular growth factors. Systemic treatment options in cases of unresectable multisite disease are limited. Multikinase inhibitors that inhibit angiogenesis, such as lenvatinib, have proven effective in several other malignancies, and may be a viable option for mPPGL. Objective: We aimed to evaluate the efficacy of lenvatinib as salvage therapy in mPPGLs. Methods: This was a retrospective analysis of mPPGL patients ≥ 18 years of age who received lenvatinib from 2015 to 2020 at a tertiary referral center. Patients were started on lenvatinib 20 mg daily and dose was adjusted according to tolerance or disease progression. Results: Eleven patients were included. Median treatment duration was 14.7 months (95% CI, 2.3-NE). Treatment was discontinued due to disease progression, adverse events, or death. Overall survival at 12 months was 80.8% (95% CI, 42.3-94.9%) but its median was not reached. Median progression-free survival was 14.7 months (95% CI, 1.7-NE). Among the 8 patients with measurable disease, overall response rate was 63%, as 5/8 experienced a partial response and 3/8 had stable disease. Worsening hypertension and anemia were the most common adverse events. Conclusion: Lenvatinib may be a viable treatment option for mPPGL, although at the potential risk of worsening hypertension. Larger, multicenter studies are needed to better characterize treatment efficacy.
- Open Access
- 21 May 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (9) , e1288
Indeterminate thyroid nodules in the era of molecular genomics
Background: Indeterminate thyroid nodules are diagnosed in up to 30% of fine‐needle aspirations and the risk of malignancy in these cases are highly variable. Consequently, managing these nodules has been a challenge. While a diagnostic thyroidectomy would help clarify the pathology, there is the risk of developing surgical‐related complications for a procedure that may not have been necessary and associated high costs. Genomic testing of indeterminate thyroid nodules may help better guide management.Methods: We present an unbiased comprehensive review of available molecular testing for classifying indeterminate thyroid nodules, as well as their strengths and limitations, with the objective to allow practitioners to choose the best testing modality for their patients.Results: Molecular testing of these nodules provided a platform to help distinguish benign versus malignant nodules, providing more confidence to rule in or rule out the likelihood of thyroid cancer in indeterminate nodules.Conclusion: Genomic testing has evolved to more comprehensive panels to better stratify indeterminate nodules, including Hürthle cell neoplasms and noninvasive follicular neoplasm with papillary‐like nuclear features. Understanding the methodology of each available test improves patient care and reduces unnecessary costs.
- 21 May 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (9) , e1288
Open AccessIndeterminate thyroid nodules in the era of molecular genomics
Background: Indeterminate thyroid nodules are diagnosed in up to 30% of fine‐needle aspirations and the risk of malignancy in these cases are highly variable. Consequently, managing these nodules has been a challenge. While a diagnostic thyroidectomy would help clarify the pathology, there is the risk of developing surgical‐related complications for a procedure that may not have been necessary and associated high costs. Genomic testing of indeterminate thyroid nodules may help better guide management.Methods: We present an unbiased comprehensive review of available molecular testing for classifying indeterminate thyroid nodules, as well as their strengths and limitations, with the objective to allow practitioners to choose the best testing modality for their patients.Results: Molecular testing of these nodules provided a platform to help distinguish benign versus malignant nodules, providing more confidence to rule in or rule out the likelihood of thyroid cancer in indeterminate nodules.Conclusion: Genomic testing has evolved to more comprehensive panels to better stratify indeterminate nodules, including Hürthle cell neoplasms and noninvasive follicular neoplasm with papillary‐like nuclear features. Understanding the methodology of each available test improves patient care and reduces unnecessary costs.